fashion -WSS

fashion

author：leisure time 2025-10-01 15:40:19 - browse：42951

Cell and gene therapy sign seen at a conference. -- biotech coverage from STAT — Jonathan Wosen for STAT

CARLSBAD, Calif. — Biotech CEOs leading cell and gene therapy companies spoke frankly at a conference here last week about the tough choices they’re making to preserve limited cash amid the industry’s ongoing slowdown.

The company leaders said that they’ve felt added pressure to use smaller teams to work quickly on fewer projects, and at times to partner with outside firms that have specific manufacturing and research expertise. Not all of these changes are bad, they added, noting that efficiency is a good trait for a biotech company in any market.

The candid conversation on Thursday was part of Meeting on the Mesa, an annual cell and gene therapy conference held in Carlsbad, in the north of San Diego County. And it provided a glimpse into discussions happening across the life science industry as biotech markets continue a sharp slump that dates back to late 2021.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： How the political right came to back psychedelics to treat trauma

WSS

Biden launches a new push to limit health care costs

HCA discloses massive data breach affecting 11 million patients

U.K. researchers warn about biases in medical devices, algorithms

Retired US general questions alleged Putin, Prigozhin meeting

Argenx readies a blockbuster opportunity with drug for autoimmune disease

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

hotspot

fashion

leisure time

At least 13 dead in Texas as scorching temps continue

Positive childhood experiences can help future health

Medicare proposal to cover medical devices draws a mixed reaction

Positive childhood experiences can help future health

The high cost of giving birth even with insurance

Leqembi, other new Alzheimer’s drugs require better biomarkers

The high cost of giving birth even with insurance

App could help diagnose ear infections more accurately — and at home

Wildfire smoke exposes gaps in outdoor worker protections

Virtual Event: March of the Biosimilars

focus

It's time to get medical device identifiers over the finish line

App could help diagnose ear infections more accurately — and at home

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

UnitedHealth increases loan offers after Change Healthcare outage

It's time to get medical device identifiers over the finish line

NIH fellows want a pay raise. Will that mean less money for grants?

explore

focus

hotspot

hotspot